ABSTRACT
Genetic susceptibility loci are associated with PDAC risk and survival, but the impact of germline HLA region variation remains largely unexplored. This study examined HLA I-II alleles within the PanGenEU study and validated our findings using external datasets (UK Biobank, TCGA, PAN-NGS trial, and Caris trial). HLA-A*02:01and HLA-B*49 alleles were linked to a decreased risk of PDAC, whereas HLA-B*39, HLA-DPB1*04, and HLA-A*26:01 were directly associated with increased risk. PDAC patients carrying the HLA-A*02:01 allele also showed lower mortality rates, with the effect being more pronounced in those with KRASG12V mutations, pointing to a host*tumor genetic interaction. This research highlights HLA-A*02:01, found in 20% of Europeans, as a marker for reduced PDAC risk and mortality, especially in KRASG12V mutated tumors. Results from this study could enhance personalized medicine for PDAC by identifying patients who may benefit from regular screenings through tailored risk assessments. Importantly, our findings are crucial for stratifying PDAC patients based on their genetic background and tumor mutational profile, which can guide treatment strategies.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work was partially supported by Pancreatic Cancer Collective (PCC): Lustgarten Foundation & Stand-Up to Cancer (SU2C #6179); Fondo de Investigaciones Sanitarias (FIS), Instituto de Salud Carlos III, Spain (#PI061614, #PI11/01542, #PI0902102, #PI12/01635, #PI12/00815, #PI15/01573, #PI18/01347, #PI21/00495); Red Tematica de Investigacion Cooperativa en Cancer, Spain (#RD12/0036/0034, #RD12/0036/0050, #RD12/0036/0073); EU-6FP Integrated Project (#018771-MOLDIAG-PACA), EU-FP7-HEALTH (#259737-CANCERALIA, #256974-EPC-TM-Net); Associazione Italiana Ricerca sul Cancro (IG 26343); Fondazione Cariverona: Oncology Biobank Project Antonio Schiavi (prot. 203885/2017); Italian Ministry of Health through Fondazione Italiana Malattie Pancreas (FIMP_CUP J37G22000230001); Cancer Focus Northern Ireland and Department for Employment and Learning; and ALF (#SLL20130022), Sweden, Cancer Research UK (C7690/A26881) and Pancreatic Cancer UK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of all participating centers contributing to PanGenEU study gave ethical approval for this work Ethics Committee of the Vall d Hebron University Hospital gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
